Therefore, we hypothesised that reversing senescence by genetic ablation of p16 may lead to recovery of functional satellite cells and MPCs, and a subsequent improvement in the DMD phenotype. The gene discussed is CDKN2A; the disease is Duchenne muscular dystrophy.